Beneficial effect of amyloid beta after controlled cortical impact

References

• Venkitaramani DV, Chin J, Netzer WJ, Gouras GK, Lesne S, Malinow R, Lombroso PJ. Beta-amyloid modulation of synaptic transmission and plasticity. Journal of Neurosciences 2007; 27: 11832–11837
   PubMed Web of Science ®Google Scholar
• Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. American Journal of Pathology 1999; 155: 853–862
   PubMed Web of Science ®Google Scholar
• Roberts GW, Gentleman SM, Lynch A, Graham DI. Beta A4 amyloid protein deposition in brain after head trauma. Lancet 1991; 338: 1422–1423
   PubMed Web of Science ®Google Scholar
• Roberts GW, Gentleman SM, Lynch A, Murray L, Landon M, Graham DI. Beta amyloid protein deposition in the brain after severe head injury: Implications for the pathogenesis of Alzheimer's disease. Journal of Neurology, Neurosurgery & Psychiatry 1994; 57: 419–425
   PubMed Web of Science ®Google Scholar
• Johnson VE, Stewart W, Smith DH. Traumatic brain injury and amyloid-beta pathology: A link to Alzheimer's disease?. Nature Reviews Neurosciences 2010; 11: 361–370
   PubMed Web of Science ®Google Scholar
• Loane DJ, Pocivavsek A, Moussa CE, Thompson R, Matsuoka Y, Faden AI, Rebeck GW, Burns MP. Amyloid precursor protein secretases as therapeutic targets for traumatic brain injury. Nature Medicine 2009; 15: 377–379
   PubMed Web of Science ®Google Scholar
• Puzzo D, Privitera L, Fa' M, Staniszewski A, Hashimoto G, Aziz F, Sakurai M, Ribe EM, Troy CM, Mercken M, et al. Endogenous amyloid-beta is necessary for hippocampal synaptic plasticity and memory. Annals of Neurology 2011; 69: 819–830
   PubMed Web of Science ®Google Scholar
• Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B, Burton MA, Goldstein LE, Duong S, Tanzi RE, et al. The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One 2010; 5: e9505
   PubMed Web of Science ®Google Scholar
• Mannix RC, Zhang J, Park J, Lee C, Whalen MJ. Detrimental effect of genetic inhibition of B-site APP-cleaving enzyme 1 on functional outcome after controlled cortical impact in young adult mice. Journal of Neurotrauma 2011; 28: 1855–1861
   PubMedGoogle Scholar
• Mannix RC, Zhang J, Park J, Zhang X, Bilal K, Walker K, Tanzi RE, Tesco G, Whalen MJ. Age-dependent effect of apolipoprotein E4 on functional outcome after controlled cortical impact in mice. Journal of Cerebral Blood Flow & Metabolism 2010; 31: 351–361
   PubMedGoogle Scholar
• Tsukuda K, Mogi M, Iwanami J, Min LJ, Sakata A, Jing F, Iwai M, Horiuchi M. Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation. Hypertension 2009; 54: 782–787
   PubMed Web of Science ®Google Scholar
• Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. Journal of Neuroscience Methods 1984; 11: 47–60
   PubMed Web of Science ®Google Scholar
• Smith DH, Nakamura M, McIntosh TK, Wang J, Rodriguez A, Chen XH, Raghupathi R, Saatman KE, Clemens J, Schmidt ML, et al. Brain trauma induces massive hippocampal neuron death linked to a surge in beta-amyloid levels in mice overexpressing mutant amyloid precursor protein. American Journal of Pathology 1998; 153: 1005–1010
   PubMed Web of Science ®Google Scholar
• Abrahamson EE, Ikonomovic MD, Dixon CE, DeKosky ST. Simvastatin therapy prevents brain trauma-induced increases in beta-amyloid peptide levels. Annals of Neurology 2009; 66: 407–414
   PubMed Web of Science ®Google Scholar
• Clark RS, Kochanek PM, Watkins SC, Chen M, Dixon CE, Seidberg NA, Melick J, Loeffert JE, Nathaniel PD, Jin KL, et al. Caspase-3 mediated neuronal death after traumatic brain injury in rats. Journal of Neurochemistry 2000; 74: 740–753
   PubMed Web of Science ®Google Scholar
• Bermpohl D, You Z, Korsmeyer SJ, Moskowitz MA, Whalen MJ. Traumatic brain injury in mice deficient in Bid: Effects on histopathology and functional outcome. Journal of Cerebral Blood Flow & Metabolism 2006; 26: 625–633
   PubMedGoogle Scholar
• Preda S, Govoni S, Lanni C, Racchi M, Mura E, Grilli M, Marchi M. Acute beta-amyloid administration disrupts the cholinergic control of dopamine release in the nucleus accumbens. Neuropsychopharmacology 2008; 33: 1062–1070
   PubMedGoogle Scholar
• Zhong P, Gu Z, Wang X, Jiang H, Feng J, Yan Z. Impaired modulation of GABAergic transmission by muscarinic receptors in a mouse transgenic model of Alzheimer's disease. Journal of Biological Chemistry 2003; 278: 26888–26896
   PubMed Web of Science ®Google Scholar
• Giuffrida ML, Caraci F, Pignataro B, Cataldo S, De Bona P, Bruno V, Molinaro G, Pappalardo G, Messina A, Palmigiano A, et al. Beta-amyloid monomers are neuroprotective. Journal of Neurosciences 2009; 29: 10582–10587
   PubMed Web of Science ®Google Scholar
• Vassar R, Kovacs DM, Yan R, Wong PC. The beta-secretase enzyme BACE in health and Alzheimer's disease: Regulation, cell biology, function, and therapeutic potential. Journal of Neurosciences 2009; 29: 12787–12794
   PubMed Web of Science ®Google Scholar
• Hook V, Toneff T, Bogyo M, Greenbaum D, Medzihradszky KF, Neveu J, Lane W, Hook G, Reisine T. Inhibition of cathepsin B reduces beta-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: Evidence for cathepsin B as a candidate beta-secretase of Alzheimer's disease. Biological Chemistry 2005; 386: 931–940
   PubMed Web of Science ®Google Scholar